据ICIS网站11月16日消息 美国制药商Moderna周一宣布了冠状病毒疫苗第三阶段试验的积极结果，该疫苗推高了全球油价和美国上市化工公司的大多数股票。
该公司在一份声明中称，对其候选疫苗的第三阶段研究在美国30000多名参与者中进行了测试，显示出94.5%的有效性。
这是对冠状病毒疫苗的第二项研究，在数周内显示出阳性结果。
美国制药巨头辉瑞公司上周宣布，其与德国免疫治疗专家BioNTech合作开发的冠状病毒疫苗，根据临床试验，至少有90%的有效性。
Moderna正在与美国疾病控制和预防中心（CDC）、Operation Warp Speed 和与美国政府签约的冠状病毒疫苗分销商McKesson合作。
该公司表示，到2020年底，他们预计将有约2000万剂药物在美国上市，并有望在2021年在全球生产5-10亿剂。
Moderna首席执行官Stéphane Bancel说：“我们第三阶段研究的这一积极的中期分析为我们提供了第一个临床验证，证明我们的疫苗可以预防包括严重疾病在内的Covid-19疾病。”
王磊 摘译自 ICIS
原文如下：
Crude values, US chem shares jump US drug maker Moderna announced positive results The company said in a release that the phase 3 study of its vaccine candidate showed 94.5% efficacy when tested among more than 30,000 participants in the US.
This is the second study US pharmaceutical major Pfizer announced last week that the coronavirus vaccine it is developing in partnership with German immunotherapy specialist BionTech is at least 90% effective based Moderna is working with the US Centers for Disease Control and Prevention (CDC), Operation Warp Speed and McKesson, a coronavirus vaccine distributor contracted by the US government.
The company said that by the end of 2020, they expect to have about 20m doses ready to ship in the US and remains “This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent Covid-19 disease, including severe disease,” said Moderna CEO Stéphane Bancel.